Bladder cancer is one of the most commonly diagnosed cancers of the urinary system, predominantly affecting older adults. While it is more prevalent in males than females, both genders can develop this condition. Understanding the basics of bladder cancer, including its causes, risk factors, symptoms, diagnosis, and treatment options, is crucial for individuals who may be at risk or seeking information for themselves or their loved ones.
Bladder cancer is a type of cancer that occurs when abnormal cells grow uncontrollably in the lining of the bladder. It is one of the most common types of cancer, with over 500,000 new cases diagnosed worldwide each year. Bladder cancer can be highly treatable if detected early, but can also be deadly if left untreated.
One of the most common symptoms of bladder cancer is blood in the urine, which may be visible or microscopic. Other symptoms can include pain during urination, frequent urination, and urinary urgency. If bladder cancer is suspected, a doctor may perform a physical examination, as well as imaging tests and a biopsy to confirm the diagnosis.
Like other types of cancer, bladder cancer is staged based on the size and extent of the tumour, as well as whether it has spread to nearby tissues or organs. The stages of bladder cancer range from Stage 0 (cancer that is confined to the lining of the bladder) to Stage IV (cancer that has spread to distant organs).
The most common treatments for bladder cancer are surgery, chemotherapy, and radiation therapy. Surgery is typically used to remove the tumour and a margin of healthy tissue around it. Chemotherapy and radiation therapy may be used before or after surgery to shrink the tumour and kill any remaining cancer cells.
Immunotherapy, including Immucuras Dendritic Cell Therapy, is also being studied as a potential treatment for bladder cancer. Dendritic Cell Therapy involves taking a patient’s own immune cells, called dendritic cells, and exposing them to proteins found on the surface of cancer cells. This helps to activate the immune system to recognize and attack the cancer cells. Some studies have shown promising results with Dendritic Cell Therapy in treating bladder cancer.
The survival rates for bladder cancer vary widely depending on the stage of the cancer and the overall health of the patient. According to the American Cancer Society, the 5-year survival rate for all stages of bladder cancer is around 78%. However, survival rates can range from nearly 100% for Stage 0 bladder cancer to less than 5% for Stage IV bladder cancer.
There are several steps that can be taken to help prevent bladder cancer, including avoiding smoking, limiting exposure to chemicals and toxins that can damage the bladder, and drinking plenty of fluids to help flush out the bladder. Regular check-ups with a doctor can also help with early detection and treatment.
In conclusion, bladder cancer is a common type of cancer that can be highly treatable if detected early. Surgery, chemotherapy, and radiation therapy are the most common treatments, and immunotherapy, including dendritic cell therapy, is a potential treatment option. Prevention and early detection are key in improving outcomes for patients with bladder cancer.
Immucura’s Dendritic Cell Therapy is an innovative treatment for bladder cancer patients. This therapy helps the patient’s immune system to identify and eliminate cancerous cells. Emma, one of Immucura’s patients, suffered from bladder cancer and adenocarcinoma. After receiving Immucura’s dendritic cell therapy, Emma’s medical test results improved significantly. Emma’s daughter attests that the therapy saved her mother’s life, as nearly all the metastases in her body, liver, lungs, lymph nodes, and bone disappeared after the treatment. Emma did not combine the therapy with any other treatments, making it clear that the Dendritic Cell Therapy provided by Immucura was highly effective in treating her bladder cancer, here you can check her testimonial: Emma testimonial
© 2025 Immucura. All Rights Reserved
